Ramipril in Rheumatoid Arthritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00273533|
Recruitment Status : Completed
First Posted : January 9, 2006
Last Update Posted : July 22, 2008
|Condition or disease||Intervention/treatment||Phase|
|Arthritis, Rheumatoid||Drug: Ramipril||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Effects of Ramipril on Endothelial Function in Patients With Rheumatoid Arthritis|
|Study Start Date :||June 2004|
|Study Completion Date :||July 2006|
- Endothelial dysfunction evaluated on weeks 8 and 16.
- Alteration of inflammatory parameters: C-reactive Protein, TNFa, Interleukin 6 on weeks 8 and 16.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273533
|Study Director:||Ali Shokry||Sanofi|